193 related articles for article (PubMed ID: 36158143)
1. Diagnosis 101: diabetic kidney disease.
Lerma EV
Clin Kidney J; 2022 Oct; 15(10):1797-1799. PubMed ID: 36158143
[TBL] [Abstract][Full Text] [Related]
2. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
Gohda T; Murakoshi M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
[TBL] [Abstract][Full Text] [Related]
3. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
Mima A
Adv Ther; 2022 Aug; 39(8):3488-3500. PubMed ID: 35751762
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk.
Stephens JW; Brown KE; Min T
Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():32-45. PubMed ID: 32267078
[TBL] [Abstract][Full Text] [Related]
5. The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes.
García-Carro C; Vergara A; Agraz I; Jacobs-Cachá C; Espinel E; Seron D; Soler MJ
J Clin Med; 2019 Jun; 8(6):. PubMed ID: 31212945
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists.
Górriz JL; Soler MJ; Navarro-González JF; García-Carro C; Puchades MJ; D'Marco L; Martínez Castelao A; Fernández-Fernández B; Ortiz A; Górriz-Zambrano C; Navarro-Pérez J; Gorgojo-Martinez JJ
J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32235471
[TBL] [Abstract][Full Text] [Related]
7. Diabetic kidney disease treatment: new perspectives.
Tong LL; Adler SG
Kidney Res Clin Pract; 2022 Sep; 41(Suppl 2):S63-S73. PubMed ID: 36239062
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
Zou H; Zhou B; Xu G
Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
[TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic agents for the treatment of diabetic kidney disease.
Hartman RE; Rao PSS; Churchwell MD; Lewis SJ
Expert Opin Investig Drugs; 2020 Nov; 29(11):1277-1293. PubMed ID: 32799584
[TBL] [Abstract][Full Text] [Related]
11. Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!
Singh AK; Singh R
World J Diabetes; 2022 Jul; 13(7):471-481. PubMed ID: 36051422
[TBL] [Abstract][Full Text] [Related]
12. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors.
Georgianos PI; Vaios V; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
Curr Pharm Des; 2021; 27(8):1043-1050. PubMed ID: 33463454
[TBL] [Abstract][Full Text] [Related]
14. The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice.
von Scholten BJ; Kreiner FF; Rasmussen S; Rossing P; Idorn T
Ther Adv Endocrinol Metab; 2022; 13():20420188221112490. PubMed ID: 35874312
[TBL] [Abstract][Full Text] [Related]
15. Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.
D'Marco L; Puchades MJ; Gandía L; Forquet C; Giménez-Civera E; Panizo N; Reque J; Juan-García I; Bermúdez V; Gorriz JL
touchREV Endocrinol; 2021 Nov; 17(2):84-87. PubMed ID: 35118452
[TBL] [Abstract][Full Text] [Related]
16. Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
Rodriguez F; Lee DJ; Gad SS; Santos MP; Beetel RJ; Vasey J; Bailey RA; Patel A; Blais J; Weir MR; Dash R
Adv Ther; 2021 Aug; 38(8):4425-4441. PubMed ID: 34254257
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions.
Tommerdahl KL; Kula AJ; Bjornstad P
Expert Opin Pharmacother; 2023 Jun; 24(8):913-924. PubMed ID: 37071054
[TBL] [Abstract][Full Text] [Related]
18. Diabetic Kidney Disease.
Bonner R; Albajrami O; Hudspeth J; Upadhyay A
Prim Care; 2020 Dec; 47(4):645-659. PubMed ID: 33121634
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
20. Diabetic Kidney Disease Back in Focus: Management Field Guide for Health Care Professionals in the 21st Century.
Alicic R; Nicholas SB
Mayo Clin Proc; 2022 Oct; 97(10):1904-1919. PubMed ID: 36202498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
